127 related articles for article (PubMed ID: 12136523)
21. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Pagel JM; Pantelias A; Hedin N; Wilbur S; Saganic L; Lin Y; Axworthy D; Hamlin DK; Wilbur DS; Gopal AK; Press OW
Cancer Res; 2007 Jun; 67(12):5921-8. PubMed ID: 17575162
[TBL] [Abstract][Full Text] [Related]
22. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
23. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
Lindén O; Hindorf C; Tennvall J; Segrén S; Wingardh K; Strand SE
Cancer; 2002 Feb; 94(4 Suppl):1270-4. PubMed ID: 11877756
[TBL] [Abstract][Full Text] [Related]
24. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
[TBL] [Abstract][Full Text] [Related]
25. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.
Marshall D; Pedley RB; Boden JA; Boden R; Melton RG; Begent RH
Br J Cancer; 1996 Mar; 73(5):565-72. PubMed ID: 8605088
[TBL] [Abstract][Full Text] [Related]
26. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
[TBL] [Abstract][Full Text] [Related]
27. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
28. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.
Yao Z; Zhang M; Kobayashi H; Sakahara H; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1995 May; 36(5):837-41. PubMed ID: 7738661
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
30. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
Peräalä-Heape M; Vihko P; Vihko R
Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
[TBL] [Abstract][Full Text] [Related]
31. [Imaging and biodistribution of 111In-labeled anti-carcinoembryonic antigen monoclonal antibodies in nude mice bearing human colon cancer xenografts].
Wu H
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):254-6. PubMed ID: 2625105
[TBL] [Abstract][Full Text] [Related]
32. Effect of conjugation on the biodistribution of 111In-labelled anti-PAP and anti-PSA monoclonal antibodies examined in nude mice with PC-82 human tumor xenografts.
Perälä-Heape M; Vihko P; Pelkonen I; Laine A; Vihko R
In Vivo; 1991; 5(2):159-65. PubMed ID: 1722716
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
[TBL] [Abstract][Full Text] [Related]
34. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
35. Three-step tumor imaging with biotinylated monoclonal antibody, streptavidin and 111In-DTPA-biotin.
Nakamoto Y; Saga T; Sakahara H; Yao Z; Zhang M; Sato N; Zhao S; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1998 Feb; 25(2):95-9. PubMed ID: 9468022
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse.
Motta-Hennessy C; Sharkey RM; Goldenberg DM
J Nucl Med; 1990 Sep; 31(9):1510-9. PubMed ID: 2395019
[TBL] [Abstract][Full Text] [Related]
37. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
Sharkey RM; Motta-Hennessy C; Pawlyk D; Siegel JA; Goldenberg DM
Cancer Res; 1990 Apr; 50(8):2330-6. PubMed ID: 2180566
[TBL] [Abstract][Full Text] [Related]
38. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
39. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.
Khawli LA; Alauddin MM; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605
[TBL] [Abstract][Full Text] [Related]
40. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]